**Executive Summary**
The 9th edition of the INDIA PHARMA conference, themed “Discover in India: Leapfrogging Life-Sciences Innovation,” is scheduled for April 13–14, 2026, at FICCI, Federation House, New Delhi. Jointly organized by the Department of Pharmaceuticals (DoP) and FICCI, the event serves as a strategic platform for industry-government dialogue to address sectoral challenges and advance India's pharmaceutical and biotechnology ecosystems. The conference aims to drive innovation, strengthen regulatory frameworks, and position India as a global leader in healthcare transformation.
**Key Points / Main Content**
**Event Evolution and Significance**
* **Historical Context:** Established in 2016, the forum has evolved through eight editions, progressing from domestic manufacturing goals to innovation-led growth and long-term national objectives like "Vision 2047."
* **Strategic Platform:** Acts as a premier global forum bringing together policymakers, regulators, industry leaders, academia, and international stakeholders to shape the sector’s roadmap.
* **Flagship Engagements:** Features a CEOs' Roundtable for direct high-level interaction, Plenary Conference Sessions, a Thematic Exhibition, and a Startup Showcase Session.
**Sectoral Economic Goals**
* **Pharmaceutical Targets:** Aims to support the industry's growth from the current US$50 billion to US$130 billion by 2030, with exports exceeding US$30 billion.
* **Biotechnology Targets:** Supports the expansion of the biotech sector from its current US$137 billion valuation toward a US$300 billion target by 2030.
* **Global Positioning:** Reinforces India's rank as 3rd globally by volume and its reputation as a reliable supplier of affordable, high-quality medicines.
**9th Edition Thematic Focus Areas**
* **Regulatory and Policy Thrust:** Focusing on regulatory agility, enabling ecosystems for innovation, and addressing regulatory challenges to enhance the ease of doing business.
* **Innovation and Technology:** Emphasis on unlocking India’s Contract Research, Development, and Manufacturing Organization (CRDMO) potential, digital transformation, biologics, and advanced therapies.
* **Resilience and Financing:** Developing a vibrant pharma financing ecosystem and ensuring supply chain resilience.
**Impact Analysis**
**Pharmaceutical and Biotechnology Industry Leaders**
**Impact:** Provides a critical platform for policy advocacy, issue resolution, and strategic collaboration with the government.
**Action Required:** Engage in the CEOs' Roundtable and thematic sessions to align corporate strategies with national growth trajectories.
**Government and Regulators (Department of Pharmaceuticals)**
**Impact:** Enables the formulation of actionable policy recommendations and strengthens global competitiveness through direct industry feedback.
**Action Required:** Lead policy discourse and establish regulatory frameworks that foster innovation and ensure access to affordable medicines.
**Startups and Emerging Innovators**
**Impact:** Offers visibility through a dedicated showcase platform for next-generation technologies and disruptive innovations.
**Action Required:** Utilize the "Startup Showcase Session" to present emerging technologies and engage with the pharma financing ecosystem.
**International Stakeholders and Investors**
**Impact:** Identifies investment pipelines and strengthens global partnerships for manufacturing and research excellence.
**Action Required:** Explore collaborations in India's expanding pharmaceutical and biotech sectors, particularly in areas like biologics and CRDMO.
Key Entities Referenced
INDIA PHARMA: A strategic platform and annual global forum for industry-government dialogue designed to create a roadmap for advancing India’s pharmaceutical ecosystem.
Department of Pharmaceuticals (DoP): The central government department responsible for pharmaceutical policy formulation, promoting research and development, and organizing the India Pharma conference.
Federation of Indian Chambers of Commerce & Industry (FICCI): The primary industry body that co-organizes the India Pharma initiative and serves as a key interface for policy advocacy and industry representation.
Vision 2047: Transformative Roadmap for the Future: A long-term strategic policy framework mentioned as the basis for aligning the pharmaceutical sector's growth with India's national goals.
Vaccine Maitri: A significant government initiative cited as an example of India’s global leadership in public health through the international supply of vaccines.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Backgrounder: India Pharma Conference
Posted On: 10 APR 2026 3:10PM by PIB Delhi
INDIA PHARMA was conceptualized in 2016 by the Federation of Indian Chambers of Commerce &
Industry in partnership with the Department of Pharmaceuticals as a strategic platform for industry–
government dialogue. The initiative was designed to identify growth opportunities, address sectoral
challenges, and create a roadmap for advancing India’s pharmaceutical ecosystem.
Over the past eight editions, INDIA PHARMA has evolved into a premier global forum bringing together
policymakers, regulators, industry leaders, academia, and international stakeholders. The platform has
played a pivotal role in shaping India’s pharmaceutical sector through policy discourse, issue resolution,
and strategic collaborations.
INDIA PHARMA has evolved significantly over the years, with each edition reflecting the changing
priorities and growth trajectory of India’s pharmaceutical sector. The 1st Edition (2016) focused on
“Make in India – Are We on Track?”, setting the tone for domestic manufacturing and self-reliance. The
2nd Edition (2017) emphasized “Responsible Healthcare”, highlighting accessibility and accountability.
The 3rd Edition (2018) focused on “Driving NextGen Pharmaceuticals”, underscoring innovation and
future-ready capabilities, followed by the 4th Edition (2019) on “Enhancing Affordable Pharmaceutical
Healthcare”.
The 5th Edition (2020) centered on “Meeting Challenges for Affordable and Quality Healthcare”,
reflecting resilience and quality systems. The 6th Edition (2021), themed “India Pharma Industry:
Future is Now”, signaled a shift towards transformation and global positioning. The 7th Edition (2022)
advanced this vision through “Vision 2047: Transformative Roadmap for the Future”, aligning with
long-term national goals. The 8th Edition (2023) focused on “Indian Pharma Industry: Delivering
Value Through Innovation”, reinforcing innovation-led growth.
A defining feature of INDIA PHARMA has been the flagship CEOs’ Roundtable, enabling direct, high-
level interactions between industry leaders and government. This forum has emerged as a key mechanism
for candid discussions on policy priorities, regulatory challenges, and future growth pathways.
Building on this strong legacy, the theme of the 9th Edition (2026) is “Discover in India: Leapfrogging
Life-Sciences Innovation”, aiming to position India at the forefront of global pharmaceutical leadership
and healthcare transformation.The event is jointly organized by the Department of Pharmaceuticals (DoP) and FICCI. The DoP plays a
central role in policy formulation, ensuring access to affordable medicines, promoting research and
development, and strengthening global competitiveness. FICCI serves as a key industry interface for
policy advocacy, industry representation, and consensus building.
India’s pharmaceutical industry is a global leader, ranking 3rd by volume and 14th by value, and
contributing approximately 1.7% to GDP. The sector is valued at around US$50 billion and is projected to
reach US$130 billion by 2030, with exports exceeding US$30 billion. India has also demonstrated global
leadership in public health through initiatives such as Vaccine Maitri, supplying nearly 300 million doses
to around 100 countries.
India’s biotechnology sector is also rapidly expanding, ranked among the top 12 globally and 3rd in the
Asia-Pacific region. With a valuation of approximately US$137 billion and a target of US$300 billion by
2030, the sector is driven by innovation, startup growth, and strong research infrastructure.
Against this backdrop, the 9th edition of INDIA PHARMA will be held on 13th–14th April 2026 in New
Delhi, marking the continuation of a strong legacy and providing a future-oriented platform to shape the
next phase of sectoral growth.
The 9th edition will focus on building a future-ready, globally competitive pharmaceutical ecosystem
by promoting innovation, strengthening regulatory frameworks, and enhancing ease of doing business. It
aims to position India as a global hub for pharmaceuticals and biotechnology by boosting investments,
expanding exports, and fostering international collaborations. The event will feature a comprehensive set
of engagements, including the flagship CEOs' Roundtable.
Key thematic sessions will cover policy thrust for catalysing innovation, enabling a regulatory
ecosystem to foster innovation, harnessing next-generation technologies for disruptive innovation,
addressing regulatory challenges, and reflections on big moves required to leapfrog innovation.
Strategic focus areas include unlocking India's CRDMO potential, regulatory agility, digital
transformation, biologics and advanced therapies, supply chain resilience, developing a vibrant pharma
financing ecosystem, and a startup showcase platform for emerging innovations.
Expected outcomes include actionable policy recommendations, strengthened global partnerships and
investment pipelines, enhanced regulatory clarity, and reinforcement of India's position as a reliable global
supplier of affordable, high-quality medicines. INDIA PHARMA 2026 will play a critical role in shaping
India's pharmaceutical sector roadmap and positioning the country at the forefront of global healthcare
innovation and manufacturing excellence.
*****
CMC-DoP
(Release ID: 2250771) Visitor Counter : 292
Read this release in: Urdu , ही